Eisai Co. Ltd. Projects Strong Revenue Growth for Leqembi® in FY 2026
Eisai Co. Ltd., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange, announced a projected revenue of JPY 143.5 billion for its Alzheimer’s drug Leqembi® for the fiscal year 2026 (April 2026 – March 2027). The projection was disclosed on May 15 2026 during a press release distributed by BioArctic AB, a research partner of Eisai.
Key Highlights of the Projection
| Item | Detail |
|---|---|
| Projected revenue for FY 2026 | JPY 143.5 billion |
| Comparative growth | 63 % increase versus the previous year’s sales |
| Royalty expectation for BioArctic | Approximately JPY 880 million (≈ 8.4 billion kronor) |
| Underlying driver | Leqembi® development based on BioArctic’s research led by founder Lars Lannf |
The projected figure represents a significant uptick in sales for Leqembi®, reinforcing the company’s strategy to expand its portfolio of high‑value specialty drugs. The royalty estimate for BioArctic aligns with the partnership model that Eisai employs for several of its collaborative ventures.
Recent Quarterly Performance
In the latest quarterly earnings presentation held on May 15 2026, Eisai reported robust results for the quarter ended March 31 2026:
- Earnings per share (EPS): Analysts averaged a forecast of JPY 12.42 per share, an increase of 243 % over the EPS of JPY 3.62 per share recorded in the same quarter a year earlier.
- Revenue: Consensus estimates placed revenue at JPY 194.61 billion, reflecting a 3.39 % growth compared to the prior year’s quarter.
These figures indicate that the company’s profitability and revenue generation are on an upward trajectory, setting a positive context for the Leqembi® forecast.
Market Context
- Stock performance: As of May 13 2026, Eisai’s closing price stood at JPY 4,721, with a 52‑week high of JPY 5,349 (September 2025) and a low of JPY 3,781 (May 2025).
- Market capitalization: The company’s market cap is approximately ¥1.32 trillion.
- Price‑to‑earnings ratio: At 30.73, the valuation reflects the market’s expectations of continued growth.
Eisai’s diverse operations—including prescription drugs, medical equipment, diagnostic drugs, and ancillary products such as foods, livestock feeds, chemicals, and agrochemicals—provide a broad revenue base. The company’s focus on specialty pharmaceuticals, particularly the rapidly expanding Alzheimer’s drug segment, is a key driver of its recent financial performance.
Strategic Implications
The forecasted revenue surge for Leqembi® underscores Eisai’s commitment to advancing its specialty drug pipeline. The partnership with BioArctic, which is expected to yield substantial royalty income, demonstrates a collaborative approach to drug development. These developments position Eisai favorably within the competitive pharmaceutical landscape, particularly in the aging‑population‑driven Alzheimer’s market.
All figures and statements are taken from publicly released information as of May 2026.
